

# Establishing the global governance to End-TB in the Korean Peninsula

---

Hojoon Sohn, PhD


Associate Professor

Seoul National University College of Medicine


November 7<sup>th</sup>, 2024

# Turbulent political climate in the Peninsula: rollercoaster ride of the hopes and despair of unified Korea

1950



● Positive Outlook ● Negative Outlook




South Korean Presidency


Periods of exchange & on-ground support (2001 – 2018)

Conflicts resulting in S. Korean casualties






## UN Sanctions, Missile & Nuclear Tests, Trade w/ N. Korea in the recent decade




### No new U.N. resolutions, fewer trade restraints



Source: Statistics Korea for total trade (2023 data not yet published), China's customs office for trade with China.




## S. Korean expectations in reunification 2018



<https://www.korea.kr/news/estNewsView.do?newsId=148852818&catelId=subjec#top50>

## S. Korean expectations in reunification since 2019

### 최근 5년간 통일인식 변화 추이 (단위: %)




(자료: 서울대학교 통일평화연구원 통일의식조사)


<https://m.go.seoul.co.kr/news/society/2023/08/18/20230818006010?cp=go>



## Current climate of humanitarian aid to N. Korea




<https://www.38north.org/2020/07/trichepukahka070220/>



Park, JH 2019 "Nevertheless" Public Perceptions of Humanitarian Aid in South Korea, KINU Online Series


Barriers  
*In planning*

# Challenges in the paths to achieving the global governance on humanitarian & health in the Korean Peninsula




# Trends in Health ODA support to N. Korea from S. Korea (2008-2017)


Cumulative ODA investment to N. Korea from S. Korea (2008-2017)



## S. Korean government support to N. Korea in Public Health & Medicine




S. Korean NGO support to N. Korea in Public Health & Medicine




# Trends in Health ODA support to N. Korea from other countries (2008-2017)


Cumulative ODA investment to N. Korea from other countries (2008-2017)



Health ODA support trend by year (other countries vs. S. Korea)



Cumulative ODA health investment by areas of support (2008-2017)





## A Strategy Toward a Unified Korea

Yo Han Lee<sup>1</sup>, Seok-Jun Yoon<sup>2</sup>, Seok Jangho Yoon<sup>7</sup>, Young Seok Shin<sup>4</sup>

<sup>1</sup>Graduate School of Public Health, Korea U

Period	Phase 1 (5 y)	Phase 2 (5 y)	Phase 3 (10 y)	Phase 4
Goals	Treat those in urgent need, especially children and women	Treat those with life-threatening problems, and provide basic health care services for the whole population	Provide basic health promotion services for the whole population and prepare infrastructure for health care system integration	Integrate health care system between South and North Korea
Affected population	6 Million	10 Million	24 Million	75 Million
Strategy	Choose 5 cities/counties in each province and set up health bases	Set up health bases throughout every city/county	Run nationwide health promotion programs Train health care professionals and	Start a national health care system in a specific area The disseminate

### Early roadmap for healthcare reconstruction in the unified Korean peninsula

- Developed during the optimistic times of S/N Korea exchange (just before domestic support discontinued)
- Macroscopic & horizontal approach for overall support
- With a mindset of re-unified Korea (→ not reflective of the current climate)
- S. Korean government centric engagement strategy
- Limited perspective(s) on the interchange between the disease specific (vertical) and health systems (horizontal) approach to improving health
- Limited assessment of the need of evidence-based approach in implementing public health strategies (data needs & use)
- Lack of global cooperative engagement strategy (Consideration of N. Korea as a global health aid target country)





## Mid-Term Strategic Plan for the Public Health and Medical Care Cooperation in the Korean Peninsula

Yun Seop Kim <sup>1</sup>, Jin-Won Noh <sup>2</sup>, Yo Han Lee <sup>3,4</sup> and Sin Gon Kim <sup>4,5</sup>

<sup>1</sup>Korea University College of Medicine, Seoul, Korea

<sup>2</sup>Division of Health Administration, College of Software and Digital Healthcare Convergence, Yonsei University, Wonju, Korea

<sup>3</sup>Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea

<sup>4</sup>Department of Healthcare and Medicine for Unified Korea, Graduate School, Korea University, Seoul, Korea

<sup>5</sup>Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea



### Established 'domestic' expert networks in health for the Korean Peninsula

Areas of support	Contents
Medical infrastructure	Modernization of health facilities and infrastructure
Nutritional support	Assessment of nutritional status and selection of priority support items
Emergency response in disaster	Assessment of emergency response cases, development of models of engagement
Infectious disease support	Assessment of past support cases, development of models of engagement
Disability support	Assessment of disability status, facilities of disabilities care

Ministry of Unification (2018)

Agenda	Health security	Easing the burden of major diseases	Resilient healthcare system	R&D cooperation	Sustainable cooperation system
Goal 1	Creating a health safety net for women and children	Establishment of joint response system for new infectious disease	Strengthening the capacity of health personnel	Developing solutions for major health problems in DPRK	Promoting Health Medical Platform in Korean Peninsula
Goal 2	Creating an environment for clean water and sanitation	Management system for major endemic infectious diseases	Modernization of healthcare facilities to provide essential health services	Developing future innovative solutions for health problems	Systematization of planning, monitoring and evaluation
Goal 3	Establishment of joint response system for environmental health crisis	Promoting of non-infectious disease management projects	Reinforcement of medical production capacity including essential medicines and equipment	R&D on the internationalization of the healthcare system in DPRK	Laying the foundation for cooperation

DPRK = Democratic People's Republic of Korea.

1. Established based on domestic expert collaboration groups → limited views and engagement of the global partners and experts
2. Lack of inter-connectivity across different health agenda → a need for prioritization of resources and development of integrated strategies

용역-2-2015-6

북한 결핵관리지원  
중장기 실행방안 수립

북한 결핵관리지원 중장기 실행방안 수립

북한 결핵관리지원  
중장기 실행방안 수립

2015. 3.

한국국제보건의료재단은 대한민국 대표 보건의료 지원 전문기관으로 개발도상국 및 북한, 국내 거주 외국인 근로자, 재외동포 등에 대한 보건의료 지원사업과 해외재난 긴급구호사업, 이종육 기증사업 등을 수행합니다.


(100-19) 서울특별시 중구 을지로 6 재능교육빌딩 6.7층  
Tel 02-6910-9000 | Fax 02-386-3155 | www.kofih.org

Key areas w/ strategic recommendation

1. Key areas of support
  - Local TB service delivery and patient management strengthening
  - Normalization of TB sanitariums
  - National TB prevalence survey and steady supply of TB drugs
  
2. Direct support plan
  - TB Active Case Finding (ACF)
  - Strengthening of TB laboratories
  - Strengthening of TB patient management
  - TB Preventive Therapy
  - National TB prevalence survey
  
3. Strategy for mass influx of N. Korea refugee entry
  - Screening of the refugee camps
  - Bacteriologic testing using NAATs
  - Treatment initiation and management in quarantine


1. High-level, theoretical and simplified strategic assessment of the future engagement strategy
2. Lack of global and intra-disciplinary cooperative engagement strategy
3. Lack of evidence-based strategic development

# The simplified process of formation of policies / strategies




***A cyclical and multi-disciplinary approach***

### End TB Strategy, 2025 milestones




### 2023 UN high-level meeting on TB, targets<sup>c</sup>



# Why should we focus on TB?

## A global perspective



Key attributes for TB (except HIV) are major public health concern for N. Korea



A need for multi-disciplinary integrated & TB specific approach for TB control efforts

**Global tuberculosis report 2024**

**TUBERCULOSIS IS THE WORLD'S LEADING INFECTIOUS DISEASE KILLER**

**1.25 MILLION TB DEATHS INCLUDING 161 000 DEATHS AMONG PEOPLE WITH HIV**

TB is also the leading cause of deaths among people with HIV and a major contributor to deaths associated with antimicrobial resistance.

**IN 2023 AN ESTIMATED 10.8 MILLION PEOPLE FELL ILL WITH TB**

**79 MILLION LIVES SAVED SINCE THE YEAR 2000 DUE TO GLOBAL EFFORTS TO COMBAT TB**

**DRUG-RESISTANT TB REMAINS A PUBLIC HEALTH CRISIS WITH GAPS IN DETECTION AND TREATMENT.**

Only about **2 IN 5 PEOPLE** with drug-resistant TB accessed treatment

**US\$ 22 BILLION REQUIRED PER YEAR FOR TB PREVENTION, DIAGNOSIS, TREATMENT AND CARE**


**US\$ 5.7 BILLION WAS AVAILABLE IN 2023** of which 80% domestic financing and US\$ 1.2 billion international financing

**US\$ 5 BILLION REQUIRED PER YEAR FOR TB RESEARCH**

**US\$ 4 BILLION FUNDING GAP**




# Why Korea?: Achievements in TB control in South Korea since 1930s




**Figure 1.** Number of tuberculosis (TB) cases per 100,000 population in South Korea, 1926–2013. Major periods are demarcated by dotted lines. Historical tuberculosis milestones for each period are briefly described. Notable tuberculosis control efforts are summarized in the boxes. GDP, gross domestic product; PPM, public–private mix. Sources: (1,4–6).

# Global Health Security (GHS) Index - 2021




# Population health outcomes in South Korea 1990–2019, and projections up to 2040: a systematic analysis for the Global Burden of Disease Study 2019

GBD 2019 South Korea BoD Collaborators\*





Leading causes 1990

Leading causes 2019



# Disease Burden in DPR Korea




	Stroke	Ischemic heart disease	COPD	Road injuries	Tuberculosis	Neonatal disorders	Low back pain	Diabetes	Lung cancer	Lower respiratory infect
<b>Democratic People's Republic of Korea</b>	1	2	3	4	5	6	7	8	9	10
Comparison group mean (Low-middle SDI)	4	3	5	10	9	2	13	7	36	6
Cambodia	1	4	11	10	6	3	14	9	19	2
Kiribati	3	2	7	16	4	5	15	1	31	8
Lao People's Democratic Republic	1	2	9	11	8	3	15	7	19	4
Marshall Islands	3	1	8	10	4	6	15	2	13	5
Micronesia (Federated States of)	2	1	6	9	18	7	12	3	10	4
Myanmar	1	2	6	12	9	3	18	5	25	7
Samoa	2	1	4	8	26	7	9	3	39	5
Tuvalu	2	1	9	8	6	5	11	3	15	4



# 북한의 결핵 문제


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2021

(Number)




## Cases attributable to five risk factors, 2021

(Number)



## Funding for TB

(US\$ millions)



# TB-specific problems for N. Korea

## 진단과 치료의 coverage

### Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2021	66% (57-76)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2021	17% (12-23)

Lower than most settings

## 결핵환자의 치료 결과

### Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	87%	89 640
Previously treated cases, excluding relapse, registered in 2020	76%	8 729
HIV-positive TB cases registered in 2020		0
MDR/RR-TB cases started on second-line treatment in 2019	72%	2 312
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019	79%	84

Better or on-par vs. most settings

## 내성결핵의 진단과 치료

### Drug-resistant TB care\*\*, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	0%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	3.6%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	270
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	815
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	0

Lower than most settings

?????!!!!

# TB-specific problems for N. Korea – Drug Resistant TB

rGLC mission report (2018)



Fig 1. DPRK MDR TB treatment centers supported by the Eugene Bell Foundation (2015).

Resistance pattern	2013 report	2016 report
MDR w/out second-line resistances	62%	68.6%
MDR w/ second-line DR (Pre-XDR)	22.8%	19.1%
MDR w/ second-line DR (XDR)	2%	6.7%

Seung & Linton (2013) and Seung, Franke & Linton (2016)

Table 3: Notification and enrolment of DR-TB cases in 2017

Drug-resistant TB care, 2017	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			4 100 (2 300–5 800)
Estimated % of TB cases with MDR/RR-TB	2.2% (0.82–4.2)	16% (9.1–25)	
% notified tested for rifampicin resistance		14%	2 116
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 1 515, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 1 732, XDR-TB: 19	


*Not a disease burden reduction*

## Drug-resistant TB care\*\*, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	0%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	3.6%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	270
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^^	815
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	0

Lower than most settings

# Investment case for TB and TB R&D



- Clear investment case for TB!
  - \$40 return per \$1 invested overall
  - \$59 return per \$1 invested for LIC & LMICs


**VS (NCDs by 2030)**



This investment yields  
a return of:

**US\$ 7**

for each dollar invested




If we don't deliver, then... (maintaining current levels of funding till 2030)

- 43 million will be infected
- 6.6 million will die of TB
- 234 million DALYs will arise
- 1 Trillion Dollars in lost due to losses in productivity




# Using modeling to inform evidence-base strategies for TB


## Post-2020 realities



- Baseline (with COVID-related disruptions)
- PPM
- + Improved diagnostics, routine TB services
- + Upstream case finding (symptomatic only)
- + Detecting subclinical TB
- + Preventive therapy (key and vulnerable populations)
- + Mass vaccination



- Baseline (with COVID-related disruptions)
- Improved diagnostics, routine TB services
- + Upstream case finding (symptomatic only)
- + Preventive therapy (key and vulnerable populations)
- + Mass vaccination



- Baseline (with COVID-related disruptions)
- Improved diagnostics, routine TB services
- + Upstream case finding (symptomatic only)
- + Detecting subclinical TB
- + Preventive therapy (key and vulnerable populations)
- + Mass vaccination



Assessment of impact scenarios for END-TB global & country level plan



Global and country level decision making



Global and country level funding decisions

# Key objectives and schematic of the global TB modeling consortium for the Korean Peninsula – a 5-year plan

**Objective 1:** Refined estimates of TB disease burden and long-term projection


**Objective 2:** Develop scenarios of required interventions to reach the End-TB goals (in both N. Korea and the Korean Peninsula)

**Objective 3:** TB cascade-specific (case-finding, patient management) strategic development and impact assessment

**Objective 4:** Assessment of budget and economic impact of TB control strategies in the Korean Peninsula

**Objective 5:** Use of consolidated model-based evidence to engage N. Korean and global stakeholders to develop engagement strategies for TB control and beyond

## Six major building blocks of the global consortium



Develop TB modeling consortium



Invitation of multiple modeling groups



Refinement of modeling methods to address uncertainties



Establish evidence-based strategies for each objective



Dissemination of results and feedback




Iterative refinement of the model-based evidence

# The policy process involving modeling...

A never-ending cycle of modeling to policy to implementation to modeling...

Models inform new policy → new data generated → models are reshaped/updated → new policy developed/updated



# Criticisms of models

- Makes assumptions based on limited Data
  - Example: protective effect of prior latent TB infection / patient care-seeking behavior based on symptom levels
- Oversimplify the world
  - Example: homogeneous mixing
- Difficult to validate
  - Any evidence that predictions will c
- Difficult to understand
  - Too much of a "black box"



All are true... but is there an alternative?!



# Decision-making w/out models?

- Expert opinion-based discussions
  - Experts create their own “mental models” of what is best!
- Predictable determinants of expert’s view
  - Recent thought patterns/events, anecdotal evidence
  - Outspoken experts more influential than silent ones
  - Experts’ own research and political agenda
  - Sound bites over substance

MIKE LUCKOICH © 2010



*How does this compare to the criticisms of the models?*


- Assumptions vs. data?
- Oversimplify the world?
- Difficult to validate?
- Difficult to understand?

- Criticisms of models are generally criticisms of the messy nature of decision-making, not models themselves


# "Garbage in, Garbage out"

Bad model  
(e.g. too simple or inadequate representation)

Good empiric data




=



Garbage Results

Poor/Garbage data

Good model



## Understanding the support priorities (first 5 years)

- Establishment of the global TB modeling consortium to develop End-TB strategy in the Korean Peninsula
- Development and execution of key evidence generation agenda for developing engagement for TB in N. Korea
- Iterative consortium meetings & global stakeholder engagement in the strategic development

## Initial Engagement (year 6-10)

- [Where Possible] N. Korean stakeholder engagement in the initial scale-up planning for evidence-based implementation
- Call for an action – recruitment of global implementing partners (w/ experience in TB) to executive specific components of the evidence-based TB engagement strategy for N. Korea
- Execution of TB model-based TB control strategy through rapid scale-up key strategies (mobile solutions for community-based interventions alongside of infrastructural development)
- Generate implementation evidence and update TB modeling to inform longer strategies

## Mid/Long-term Engagement (year 11 and beyond)


- Review and re-strategize long-term TB control policy and efforts for N. Korea
- Optimize TB case finding and service delivery through operational research
- Optimization of TB service integration alongside modernization of health systems
- Reassessment of TB care service delivery gaps and inclusion of post-TB care
- Improved research cooperation and identify research opportunities to improve TB disease burden and health systems components relevant for TB
- Develop longer term 'TB free' Korean Peninsula strategy alongside the health systems strengthening
- Strengthen the global engagement in the Korean Peninsula




# Some food for thought

Strengthening laboratory system through vertical vs. horizontal approach

## Mobile screening




*Initially for TB, but extendable to other diagnoses*



<https://images.app.goo.gl/kXjqLfUWw2egXz4p7>



# AI-Hotspot mapping



## Benefits in TB ACF

1. Improved operational efficiency
2. Improve program yields (in case finding)
3. Improved cost-efficiency & effectiveness
4. Improved decision in prioritizing areas for TB service network strengthening

## Potential challenges and limitations

1. Data availability (reliance on routine data – disease surveillance infrastructure level dependent)
2. Methods used to assess 'hot' spots (spatial homogeneity → patient movement not reflected)
3. Screening success depends on patient and community acceptance → outreach should always include community programs to reduce disease stigma, education for awareness & risk communication

Be a global friend to  **END  
TB** with Korea



**Thank you**